

	AVASTIN	LUCENTIS	EYLEA	rolucizumab
Baseline Q4 2017	49%	22%	29%	
Q12018	47%	26%	27%	
Q2	48%	21%	32%	
Q3	47%	28%	25%	
Q4	54%	26%	20%	
Q1 2019 (Pre-appr	45%	28%	27%	
Q1 2019 (Post-app	48%	27%	25%	
Q2	45%	24%	31%	
Q3	44%	24%	32%	
Q4	44%	21%	35%	
Q1 2020	38%	17%	41%	4%
Q2	37%	22%	37%	4%
Q3	42%	14%	35%	9%
Q4	39%	17%	38%	6%
Q2 2021	40%	18%	37%	5%